The Role of Supportive Therapy in Pediatric Malignancies

1. Marinca M, Miron L, Miron I. Terapia suportiva si simptomatica, in L. Miron, Terapia oncologica-optiuni bazate pe evidente. Institutul European, Iasi, 2008,799-862Search in Google Scholar

2. Segal BH, Walsh J, Gea-Bannaloche JC, et al. Infections in the cancer patients, in Devita VT Jr, Rosenberg S, Hellman SA, eds. Cancer: Principles and practice of oncology. 7th ed Philadelphia: Lippincott, Williams&Wilkins, 2005,2461-2514Search in Google Scholar

3. Safdar N, Crnich CJ, Maki DG. Infectious complications of cancer therapy, in Chang AE, Ganz PA, Hayes DF, eds. Oncology- an evidence based approach. New York, Springer, 2006,1363-1400.10.1007/0-387-31056-8_76Search in Google Scholar

4. Richard A. Larson, Richard K. Dodge, Charles A. Linker et al. A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111. Blood Journal 1998;92(5):1556-1564Search in Google Scholar

5. Anca Bacârea, Bogdana Dorcioman, Minodora Dobreanu et al. Tratamentul leucemiei acute mieloide – între beneficiu terapeutic si patologie iatrogenă – prezentare de caz. Revista Română de Medicină de Laborator Martie 2008;10(1):33-39Search in Google Scholar

6. Primic-Zakelj M. Cancer epidemiology, in Scrijvers D, Senn HJ, Mellstedt H, Zakotnk B (eds) European Society of Medical Oncology Handbook of Cancer Prevention. Informa Healthcare 2008,1-28.10.3109/9780203091531.001Search in Google Scholar

7. Ph.Lanzkowsky. Manual of pediatric hematology and oncology-fourth edition, 2005;548-56010.1016/B978-012088524-4/50023-6Search in Google Scholar

8. Kondo M. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. Immunological reviews. 2010;238(1):37-46. doi:10.1111/j.1600-065X.2010.00963Search in Google Scholar

9. Caselli D, Paolicchi O. Empiric antibiotic therapy in a child with cancer and suspected septicemia. Pediatric Reports. 2012;4(1):e2. doi:10.4081/pr.2012.e2.10.4081/pr.2012.e2335761522690308Search in Google Scholar

10. Garcia JB, Lei X, Wierda W, et al. Pneumonia during Remission Induction Chemotherapy in Patients with Acute Leukemia. Annals of the American Thoracic Society. 2013;10(5):432-440. doi:10.1513/AnnalsATS.201304-097OC10.1513/AnnalsATS.201304-097OC396091123987587Search in Google Scholar

11. Barkati S, Dufresne SF, Bélanger S, et al. Incidence of invasive aspergillosis following remission–induction chemotherapy for acute leukemia: a retrospective cohort study in a single Canadian tertiary care centre. CMAJ Open. 2014;2(2):E86-E93. doi:10.9778/cmajo.20130062.10.9778/cmajo.20130062411406125077134Search in Google Scholar

12. Huang L. Clinical and translational research in Pneumocystis and Pneumocystis pneumonia. Parasite : journal de la Société Française de Parasitologie. 2011;18(1):3-11. doi:10.1051/parasite/201118100310.1051/parasite/2011181003367140121395200Search in Google Scholar

13. Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for herpes zoster: population based case-control study. BMJ : British Medical Journal. 2014;348:g2911. doi:10.1136/bmj.g2911.10.1136/bmj.g2911401978225134101Search in Google Scholar

14. Hernández-García S, Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer. Nutr Cancer. 2015;67(7):1159-69. doi: 10.1080/01635581.2015.1068819. Epub 2015 Aug 4.10.1080/01635581.2015.106881926241555Search in Google Scholar